RM
Therapeutic Areas
Sanara MedTech Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CellerateRX® Gel | Surgical/Wound Management | Approved/Commercial |
| CellerateRX® Surgical Powder | Surgical/Wound Management | Approved/Commercial |
| BIASURGE® Advanced Surgical Solution | Surgical Irrigation | Approved/Commercial |
| FORTIFY TRG® Tissue Repair Graft | Soft Tissue Repair | Approved/Commercial |
| FORTIFY FLOWABLE® Extracellular Matrix | Soft Tissue Repair | Approved/Commercial |
| TEXAGEN® Amniotic Membrane Allograft | Wound and Surgical Repair | Approved/Commercial |
| ALLOCYTE® Plus Advanced Viable Bone Matrix | Bone Grafting | Approved/Commercial |
| BiFORM® Bioactive Moldable Matrix | Bone Void Filling | Approved/Commercial |
Leadership Team at Sanara MedTech
RB
Robert Bearden
Senior Vice President, Clinical and Medical Affairs
NB
Nina Bionda
Chief R&D Officer
NG
Nicholas Gachassin, III
General Counsel
TP
Tyler Palmer
Chief Corporate Development and Strategy Officer
BD
Bob DeSutter
Director
EM
Eric Major
Director